Furthermore, PD-L1 expression in tumor cells and in tumor-infiltrating immune cells is associated with poor clinical outcome (cancer-specific death, p < 0.05) [57], without a predictive role of response to cabozantinib and axitinib plus anti-PD1/PD-L1 [4,58,59,60,61]. This evidence concerns the gene CD274 and neoplasm.